Astro Pak launches decontamination services subsidiary
Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.
SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.
The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.
The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.
Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.
In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
You may also like
Manufacturing
Viatris to cut 10% of its global workforce after Indian plant fire
Read moreViatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Lario Therapeutics secures $2.4m from MJFF and Wellcome to expand CNS calcium channel programmes
The company has been awarded $2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's Research and Wellcome to advance its neuronal calcium channel platform into Parkinson's disease and post-traumatic stress disorder
Research & Development
Horizon Europe 2025 grant backs Phase II trial of HER-096 for Parkinson’s disease
Herantis Pharma has secured selection for €8m in non-dilutive funding under Horizon Europe to advance a Phase II proof-of-concept study of its subcutaneously delivered Parkinson’s therapy candidate HER-096